ガバペンチン市場-世界の産業規模、シェア、動向、機会、予測、形態別、タイプ別、用途別、流通経路別、地域別、競合、2019～2029年

ガバペンチンの世界市場は2023年に19億3,000万米ドルと評価され、2029年のCAGRは5.56%で、予測期間中に堅調な成長が予測されています。

世界のガバペンチン市場は、神経疾患や慢性疼痛症状の世界の有病率の増加を反映して、近年著しい成長と進化を遂げています。抗痙攣・鎮痛薬であるガバペンチンは、てんかん、神経障害性疼痛、レストレスレッグス症候群などの病態管理に有効であることから脚光を浴びています。市場の成長を後押ししているのは、これらの疾患と診断される患者数の急増と、慢性疼痛に罹患しやすい高齢化社会の拡大です。製薬企業は、ガバペンチンの応用範囲を拡大するために研究開発に積極的に投資しており、製剤やデリバリー方法の革新を促進しています。北米は伝統的にガバペンチンの主要市場であり、神経疾患の罹患率が高く、医療インフラが確立していることがその要因となっています。しかし、アジア太平洋やラテンアメリカ新興国では、神経疾患に対する意識の高まりや医療へのアクセスの改善により、ガバペンチンの需要が増加しています。市場力学はまた、ジェネリック医薬品の競争にも影響されます。特許の失効によって費用対効果の高い代替品が入手可能になり、ブランド製剤の市場優位性が脅かされているからです。

市場が成熟を続ける中、規制状況の進展と治療ガイドラインの進化が競合情勢の形成に極めて重要な役割を果たしています。メーカー各社は、市場での地位を強化するため、規制当局の承認取得、臨床試験の実施、提携に戦略的に注力しています。

主要市場の促進要因

神経疾患の有病率の上昇

高齢化人口の拡大

神経疾患に対する認識と診断の高まり

主要市場課題

規制の厳しさと承認の遅れ

ジェネリック医薬品の競合と価格圧力

主要市場動向

ドラッグ製剤とデリバリー方法の革新

患者中心の取り組みと支援プログラム

セグメント別洞察

製品別洞察

タイプ別洞察

流通チャネル別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 ガバペンチンの世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 剤形別（錠剤、カプセル剤、内用液剤）
  • タイプ別（ジェネリック、ブランド）
  • 用途別（てんかん、神経障害性疼痛、むずむず脚症候群、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 形態別
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋のガバペンチン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のガバペンチン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のガバペンチン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のガバペンチン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのガバペンチン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と新興国市場開拓

• 製品発表
• 合併・買収

第12章 ガバペンチンの世界市場のSWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Zydus Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Ascend Laboratories, LLC
• Apotex Inc.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma.
• Amneal Pharmaceuticals LLC.
• Cipla Ltd.
• BP Pharmaceuticals Laboratories Company

第15章 戦略的提言

第16章 戦略的提言当社について免責事項

Global Gabapentin Market was valued at USD 1.93 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 5.56% through 2029. The global gabapentin market has experienced significant growth and evolution in recent years, reflecting the increasing prevalence of neurological disorders and chronic pain conditions worldwide. Gabapentin, an anticonvulsant and analgesic medication, has gained prominence for its effectiveness in managing conditions such as epilepsy, neuropathic pain, and restless legs syndrome. The market's growth is propelled by a surge in the number of patients diagnosed with these disorders, coupled with an expanding aging population susceptible to chronic pain. Pharmaceutical companies are actively investing in research and development to expand the scope of gabapentin applications, fostering innovation in formulations and delivery methods. North America has traditionally been a key market for gabapentin, driven by a high incidence of neurological disorders and a well-established healthcare infrastructure. However, emerging economies in Asia-Pacific and Latin America are witnessing a rising demand for gabapentin due to increasing awareness of neurological conditions and improving access to healthcare. The market dynamics are also influenced by the generic competition, as patent expirations have led to the availability of cost-effective alternatives, challenging the market dominance of branded formulations.

As the market continues to mature, regulatory developments and evolving treatment guidelines play a pivotal role in shaping the competitive landscape. Manufacturers are strategically focusing on securing regulatory approvals, conducting clinical trials, and engaging in partnerships to strengthen their market position.

Key Market Drivers

Rising Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is a pivotal factor propelling the Global Gabapentin Market to new heights. Neurological conditions, encompassing a spectrum of disorders like epilepsy, neuropathic pain, and restless legs syndrome, have witnessed a notable increase in incidence globally. The aging population, coupled with lifestyle factors, contributes to the heightened prevalence of these disorders, creating a burgeoning demand for effective treatment options.

Gabapentin, renowned for its efficacy in managing neuropathic pain and seizures, has emerged as a cornerstone in addressing the therapeutic needs of individuals grappling with these neurological challenges. As diagnostic capabilities improve and awareness regarding these conditions expands, more patients are accurately diagnosed, fueling the demand for gabapentin.

Moreover, the medication's versatility in managing various neurological disorders positions it as a preferred choice for healthcare providers seeking a comprehensive solution. Pharmaceutical companies are strategically aligning their research and development efforts to cater specifically to the growing demand for neurological therapeutics, further boosting the prominence of gabapentin in the market.

The rising prevalence of neurological disorders not only underscores the critical need for effective treatments but also signifies the substantial growth potential for the Global Gabapentin Market. As healthcare systems worldwide prioritize the management of neurological conditions, gabapentin is expected to play an increasingly crucial role in improving the quality of life for individuals affected by these disorders, ensuring its continued prominence in the pharmaceutical landscape.

Expanding Aging Population

The expanding aging population worldwide has become a significant driver for the global Gabapentin market. As individuals age, they often experience a higher prevalence of chronic conditions such as neuropathic pain, postherpetic neuralgia, and restless legs syndrome, for which Gabapentin is commonly prescribed. Gabapentin, an anticonvulsant medication, has demonstrated efficacy in managing these conditions by modulating the activity of certain neurotransmitters in the brain. The rise in the aging demographic has led to an increased demand for pharmaceutical interventions to alleviate the associated pain and discomfort, consequently propelling the global market for Gabapentin.

The aging population's impact on the market is multifaceted. The sheer size of the elderly demographic contributes to a larger pool of potential consumers for Gabapentin and related medications. as individuals age, there is often a higher likelihood of developing chronic conditions that necessitate long-term pharmacological management, creating a sustained demand for drugs like Gabapentin. Furthermore, the expanding aging population is often accompanied by an increased awareness and diagnosis of neurological and pain-related disorders, leading to a surge in prescriptions for Gabapentin.

The global Gabapentin market is also influenced by evolving healthcare infrastructures and a growing emphasis on improving the quality of life for the elderly. With a focus on geriatric care, healthcare providers are more inclined to prescribe medications like Gabapentin to address the unique health challenges faced by the aging population. Pharmaceutical companies, recognizing this trend, are investing in research and development to expand the applications of Gabapentin, leading to innovations and new formulations.

Growing Awareness and Diagnosis of Neurological Conditions

The global Gabapentin market is experiencing a notable upswing due to the growing awareness and diagnosis of neurological conditions. In recent years, there has been a heightened recognition of various neurological disorders, including but not limited to neuropathic pain, postherpetic neuralgia, and restless legs syndrome. This increased awareness has led to a greater number of individuals seeking medical attention for their symptoms, resulting in a surge in diagnoses. As healthcare professionals become more adept at identifying and classifying neurological conditions, the demand for effective treatments such as Gabapentin has risen significantly.

The rise in awareness can be attributed to several factors, including advancements in medical research, increased health literacy among the general population, and proactive healthcare campaigns. Patients are now more informed about the symptoms of neurological disorders, prompting them to consult healthcare providers for timely diagnosis and intervention. Moreover, healthcare professionals are better equipped to recognize and diagnose these conditions, aided by improved diagnostic tools and guidelines.

The growing awareness of neurological conditions has a direct impact on the prescription patterns of healthcare providers. Gabapentin, known for its efficacy in managing various neurological symptoms, has become a frontline treatment option. As a result, pharmaceutical companies are witnessing a growing market for Gabapentin, with increased demand driven by the expanding pool of diagnosed patients.

The global Gabapentin market is also shaped by the broader societal emphasis on mental and neurological well-being. With mental health gaining recognition as a crucial aspect of overall health, there is a growing willingness among individuals to seek medical help for neurological symptoms. This cultural shift further fuels the demand for medications like Gabapentin, positioning it as a key player in addressing the therapeutic needs of individuals grappling with neurological conditions.

Key Market Challenges

Regulatory Stringency and Approval Delays

Regulatory stringency and approval delays have emerged as significant hurdles for the global gabapentin market, impacting the timely introduction of new formulations and applications. The pharmaceutical industry, inherently subject to rigorous regulatory processes, encounters varying approval landscapes across different regions, leading to complexities that hinder market entry.

The prolonged approval timelines can be attributed to the exhaustive nature of the regulatory requirements, which demand comprehensive clinical trial data and robust documentation. These challenges are further exacerbated by the need to align with evolving regulatory standards and guidelines. Manufacturers navigating the global gabapentin market must navigate through a maze of regulatory intricacies, balancing the imperative for thorough scrutiny with the necessity for timely market access.

In the face of regulatory hurdles, collaboration with regulatory authorities becomes crucial. Establishing transparent communication channels can facilitate a smoother approval process, allowing for the exchange of information and clarification of regulatory expectations. Manufacturers should proactively engage with regulatory agencies to address potential concerns and streamline approval pathways.

Furthermore, the gabapentin market's response to regulatory challenges necessitates a commitment to investing in research and development that adheres to regulatory standards. Robust and well-documented clinical trials can expedite the approval process by providing the necessary evidence of efficacy and safety.

Generic Competition and Pricing Pressures

Generic competition and pricing pressures are posing significant challenges to the global gabapentin market, reshaping the industry landscape and impacting both manufacturers and consumers alike. As patents for branded formulations expire, the market becomes flooded with generic alternatives, intensifying competition and prompting pricing pressures. While the proliferation of generic gabapentin enhances affordability for patients, it places the onus on original manufacturers to distinguish their products and maintain market share.

The increasing availability of cost-effective generic versions has led to a shift in prescribing patterns, with healthcare providers often opting for lower-cost alternatives. This dynamic challenges the revenue streams of branded gabapentin formulations, necessitating strategic responses from original manufacturers. To counteract generic competition, companies must explore avenues for innovation, perhaps through the development of extended-release formulations, novel drug combinations, or other differentiating factors that justify premium pricing.

For patients, the advent of generic alternatives offers a more accessible option, potentially reducing out-of-pocket expenses. However, for pharmaceutical companies investing in the research and development of gabapentin, the pricing pressures can stifle the incentive for innovation. Striking a balance between affordability and sustaining a viable market for new developments is critical.

Key Market Trends

Innovations in Drug Formulations and Delivery Methods

Innovations in drug formulations and delivery methods are playing a crucial role in propelling the global Gabapentin market to new heights. As pharmaceutical technology advances, there is a continuous effort to enhance the efficacy, bioavailability, and patient compliance of medications. In the case of Gabapentin, which is widely prescribed for neurological disorders, these innovations are reshaping the landscape of treatment options.

One key area of innovation is the development of extended-release formulations of Gabapentin. These formulations aim to provide a sustained release of the medication over an extended period, allowing for less frequent dosing and better adherence to prescribed regimens. This not only improves patient convenience but also contributes to the overall effectiveness of treatment by maintaining a more consistent therapeutic level of Gabapentin in the bloodstream.

Moreover, advancements in drug delivery methods are enhancing the overall patient experience. For instance, transdermal patches and novel oral delivery systems are being explored to optimize the absorption of Gabapentin, offering alternatives to traditional oral tablets. These innovations not only offer potential benefits in terms of reduced side effects and improved bioavailability but also cater to patients who may have difficulty swallowing or experience gastrointestinal issues with conventional oral medications.

In addition to novel formulations, technology-driven innovations are making waves in the Gabapentin market. Telemedicine and digital health platforms are increasingly integrated into healthcare systems, facilitating remote patient monitoring and personalized treatment plans. This technological integration enhances the accessibility of Gabapentin prescriptions, ensuring that patients can receive timely adjustments to their treatment regimens and adhere to prescribed courses effectively.

Patient-Centric Initiatives and Support Programs

Patient-centric initiatives and support programs are emerging as key drivers in boosting the global Gabapentin market. Recognizing the multifaceted challenges faced by individuals prescribed Gabapentin for neurological conditions, pharmaceutical companies and healthcare providers are increasingly focusing on initiatives that prioritize patient well-being. These programs encompass a range of support services, from educational resources and counseling to financial assistance, ultimately enhancing patient adherence and satisfaction.

One significant aspect of these initiatives is patient education. Comprehensive information about the medication, its potential side effects, and the expected outcomes is being made readily available to patients. This not only empowers individuals to make informed decisions about their treatment but also fosters a sense of control and confidence in managing their health. Educational campaigns are helping demystify neurological disorders, reducing stigma, and encouraging open communication between patients and healthcare providers.

Financial support programs are another critical component of patient-centric initiatives. Given the often-chronic nature of neurological conditions, long-term medication use is common. To alleviate the financial burden on patients, pharmaceutical companies are offering assistance programs, discounts, or copay support for Gabapentin. These measures enhance affordability and access, ensuring that financial constraints do not hinder patients from receiving the necessary treatment.

Moreover, patient support goes beyond the prescription. Many initiatives focus on holistic well-being by providing counseling services and support groups for individuals navigating the challenges associated with neurological disorders. These support networks create a sense of community, allowing patients to share experiences, coping mechanisms, and advice, thereby promoting mental and emotional well-being.

The implementation of patient-centric initiatives aligns with the broader trend of personalized medicine, tailoring healthcare experiences to individual needs. In the context of the global Gabapentin market, these initiatives contribute not only to improved patient outcomes but also to increased brand loyalty and market growth.

Segmental Insights

Product Insights

Based on the Form, Capsules emerged as the dominant segment in the global market for GlobalGabapentin in 2023.Capsules are generally easier to swallow compared to tablets, which can be particularly beneficial for individuals who may have difficulty swallowing or experience discomfort with larger tablet forms. This characteristic enhances patient compliance and contributes to a positive overall treatment experience. Capsules provide a more precise dosage compared to oral solutions. Each capsule contains a pre-measured amount of gabapentin, ensuring accuracy in dosage administration. This precision is crucial for the effective management of neurological disorders and chronic pain conditions, where maintaining a consistent therapeutic level is essential. Capsules offer excellent stability and a longer shelf life compared to oral solutions, which can be sensitive to environmental factors such as light and temperature. The stability of capsules ensures that the medication retains its potency over an extended period, reducing the risk of degradation and enhancing the reliability of the treatment.

Type Insights

Based on the Type, Generic emerged as the dominant segment in the global market for Global Gabapentin Market in 2023.The widespread utilization of generic formulations is a key factor driving the high demand in the Global Gabapentin Market. Generic versions of medications, including Gabapentin, offer the same active ingredients and therapeutic effects as their brand-name counterparts but at a lower cost. This cost-effectiveness makes generic Gabapentin an attractive option for both healthcare providers and patients, contributing to its widespread adoption. Generic drugs undergo a rigorous approval process to ensure they meet the same safety, efficacy, and quality standards as the original brand-name products. Once a brand-name drug's patent expires, generic manufacturers can enter the market, leading to increased competition. This competition often results in a significant reduction in the price of the medication, making it more affordable for healthcare systems, insurers, and individual consumers.

Distribution Channel Insights

Based on the Distribution Channel, retail pharmacy emerged as the dominant segment in the global market for Global Gabapentin Market in 2023.This is ascribed due to several reasons. Firstly,gabapentin is commonly prescribed for various conditions like neuropathic pain, seizures, and restless legs syndrome, leading to widespread demand. Secondly, retail pharmacies offer easy accessibility to patients, making it convenient for them to obtain prescriptions and refills. Additionally, the availability of generic versions of gabapentin in retail pharmacies makes it affordable for patients without insurance coverage. Moreover, retail pharmacies often provide patient education and counseling services, increasing patient compliance and satisfaction. Overall, the retail pharmacy segment's widespread accessibility, affordability, and patient-centric services contribute to its dominance in the global gabapentin market.

Regional Insights

North America emerged as the dominant player in the Global Gabapentin Market in 2023, holding the largest market share. North America is home to a robust pharmaceutical industry with several key players actively engaged in the development, manufacturing, and marketing of pharmaceutical products. The presence of these pharmaceutical companies contributes to a competitive market, with innovative formulations and effective marketing strategies that enhance the market share of gabapentin.Chronic pain conditions, for which gabapentin is often prescribed, are on the rise in North America. The region's aging population, coupled with lifestyle factors and a growing awareness of chronic pain issues, has led to an increased demand for effective pain management solutions, further propelling the gabapentin market.

Key Market Players

Zydus Pharmaceuticals, Inc.

Glenmark Pharmaceuticals Limited

Sun Pharmaceutical Industries Ltd.

Ascend Laboratories, LLC

Apotex Inc.

Teva Pharmaceutical Industries Ltd.

Aurobindo Pharma.

Amneal Pharmaceuticals LLC.

Cipla Ltd.

BP Pharmaceuticals Laboratories Company

Report Scope:

In this report, the Global Gabapentin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Gabapentin Market,By Form:

• Tablet
• Capsule
• Oral Solution

Global Gabapentin Market,By Type:

• Generic
• Branded

Global Gabapentin Market,By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Gabapentin Market,By Application:

• Epilepsy
• Neuropathic Pain
• Restless Legs Syndrome
• Others

Global Gabapentin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gabapentin Market.

Available Customizations:

Global Gabapentin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Gabapentin Market Outlook

• 4.1.Market Size Forecast
  • 4.1.1.By Value
• 4.2.Market Share Forecast
  • 4.2.1.By Form (Tablet, Capsule, Oral Solution)
  • 4.2.2.By Type (Generic, Branded)
  • 4.2.3.By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others)
  • 4.2.4.By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 4.2.5.By Region
  • 4.2.6.By Company (2023)
• 4.3.Market Map
  • 4.3.1.By Form
  • 4.3.2.By Type
  • 4.3.3.By Application
  • 4.3.4.By Distribution Channel
  • 4.3.5.By Region

5.Asia Pacific Gabapentin Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Form
  • 5.2.2.By Type
  • 5.2.3.By Application
  • 5.2.4.By Distribution Channel
  • 5.2.5.By Country
• 5.3.Asia Pacific: Country Analysis
  • 5.3.1.China Gabapentin Market Outlook
    • 5.3.1.1.Market Size Forecast
      • 5.3.1.1.1.By Value
    • 5.3.1.2.Market Share Forecast
      • 5.3.1.2.1.By Form
      • 5.3.1.2.2.By Type
      • 5.3.1.2.3.By Application
      • 5.3.1.2.4.By Distribution Channel
  • 5.3.2.India Gabapentin Market Outlook
    • 5.3.2.1.Market Size Forecast
      • 5.3.2.1.1.By Value
    • 5.3.2.2.Market Share Forecast
      • 5.3.2.2.1.By Form
      • 5.3.2.2.2.By Type
      • 5.3.2.2.3.By Application
      • 5.3.2.2.4.By Distribution Channel
  • 5.3.3.Australia Gabapentin Market Outlook
    • 5.3.3.1.Market Size Forecast
      • 5.3.3.1.1.By Value
    • 5.3.3.2.Market Share Forecast
      • 5.3.3.2.1.By Form
      • 5.3.3.2.2.By Type
      • 5.3.3.2.3.By Application
      • 5.3.3.2.4.By Distribution Channel
  • 5.3.4.Japan Gabapentin Market Outlook
    • 5.3.4.1.Market Size Forecast
      • 5.3.4.1.1.By Value
    • 5.3.4.2.Market Share Forecast
      • 5.3.4.2.1.By Form
      • 5.3.4.2.2.By Type
      • 5.3.4.2.3.By Application
      • 5.3.4.2.4.By Distribution Channel
  • 5.3.5.South Korea Gabapentin Market Outlook
    • 5.3.5.1.Market Size Forecast
      • 5.3.5.1.1.By Value
    • 5.3.5.2.Market Share Forecast
      • 5.3.5.2.1.By Form
      • 5.3.5.2.2.By Type
      • 5.3.5.2.3.By Application
      • 5.3.5.2.4.By Distribution Channel

6.Europe Gabapentin Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Form
  • 6.2.2.By Type
  • 6.2.3.By Application
  • 6.2.4.By Distribution Channel
  • 6.2.5.By Country
• 6.3.Europe: Country Analysis
  • 6.3.1.France Gabapentin Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Form
      • 6.3.1.2.2.By Type
      • 6.3.1.2.3.By Application
      • 6.3.1.2.4.By Distribution Channel
  • 6.3.2.Germany Gabapentin Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Form
      • 6.3.2.2.2.By Type
      • 6.3.2.2.3.By Application
      • 6.3.2.2.4.By Distribution Channel
  • 6.3.3.Spain Gabapentin Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Form
      • 6.3.3.2.2.By Type
      • 6.3.3.2.3.By Application
      • 6.3.3.2.4.By Distribution Channel
  • 6.3.4.Italy Gabapentin Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Form
      • 6.3.4.2.2.By Type
      • 6.3.4.2.3.By Application
      • 6.3.4.2.4.By Distribution Channel
  • 6.3.5.United Kingdom Gabapentin Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Form
      • 6.3.5.2.2.By Type
      • 6.3.5.2.3.By Application
      • 6.3.5.2.4.By Distribution Channel

7.North America Gabapentin Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Form
  • 7.2.2.By Type
  • 7.2.3.By Application
  • 7.2.4.By Distribution Channel
  • 7.2.5.By Country
• 7.3.North America: Country Analysis
  • 7.3.1.United States Gabapentin Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Form
      • 7.3.1.2.2.By Type
      • 7.3.1.2.3.By Application
      • 7.3.1.2.4.By Distribution Channel
  • 7.3.2.Mexico Gabapentin Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Form
      • 7.3.2.2.2.By Type
      • 7.3.2.2.3.By Application
      • 7.3.2.2.4.By Distribution Channel
  • 7.3.3.Canada Gabapentin Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Form
      • 7.3.3.2.2.By Type
      • 7.3.3.2.3.By Application
      • 7.3.3.2.4.By Distribution Channel

8.South America Gabapentin Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Form
  • 8.2.2.By Type
  • 8.2.3.By Application
  • 8.2.4.By Distribution Channel
  • 8.2.5.By Country
• 8.3.South America: Country Analysis
  • 8.3.1.Brazil Gabapentin Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Form
      • 8.3.1.2.2.By Type
      • 8.3.1.2.3.By Application
      • 8.3.1.2.4.By Distribution Channel
  • 8.3.2.Argentina Gabapentin Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Form
      • 8.3.2.2.2.By Type
      • 8.3.2.2.3.By Application
      • 8.3.2.2.4.By Distribution Channel
  • 8.3.3.Colombia Gabapentin Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Form
      • 8.3.3.2.2.By Type
      • 8.3.3.2.3.By Application
      • 8.3.3.2.4.By Distribution Channel

9.Middle East and Africa Gabapentin Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Form
  • 9.2.2.By Type
  • 9.2.3.By Application
  • 9.2.4.By Distribution Channel
  • 9.2.5.By Country
• 9.3.MEA: Country Analysis
  • 9.3.1.South Africa Gabapentin Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Form
      • 9.3.1.2.2.By Type
      • 9.3.1.2.3.By Application
      • 9.3.1.2.4.By Distribution Channel
  • 9.3.2.Saudi Arabia Gabapentin Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Form
      • 9.3.2.2.2.By Type
      • 9.3.2.2.3.By Application
      • 9.3.2.2.4.By Distribution Channel
  • 9.3.3.UAE Gabapentin Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Form
      • 9.3.3.2.2.By Type
      • 9.3.3.2.3.By Application
      • 9.3.3.2.4.By Distribution Channel
  • 9.3.4.Egypt Gabapentin Market Outlook
    • 9.3.4.1.Market Size Forecast
      • 9.3.4.1.1.By Value
    • 9.3.4.2.Market Share Forecast
      • 9.3.4.2.1.By Form
      • 9.3.4.2.2.By Type
      • 9.3.4.2.3.By Application
      • 9.3.4.2.4.By Distribution Channel

10.Market Dynamics

• 10.1.Drivers
• 10.2.Challenges

11.Market Trends Developments

• 11.1.Recent Developments
• 11.2.Product Launches
• 11.3.Mergers Acquisitions

12.Global Gabapentin Market: SWOT Analysis

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Product

14.Competitive Landscape

• 14.1.Zydus Pharmaceuticals, Inc.
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Products Services
  • 14.1.4.Financials (In case of listed)
  • 14.1.5.Recent Developments
  • 14.1.6.SWOT Analysis
• 14.2.Glenmark Pharmaceuticals Limited
• 14.3.Sun Pharmaceutical Industries Ltd.
• 14.4.Ascend Laboratories, LLC
• 14.5.Apotex Inc.
• 14.6.Teva Pharmaceutical Industries Ltd.
• 14.7.Aurobindo Pharma.
• 14.8.Amneal Pharmaceuticals LLC.
• 14.9.Cipla Ltd.
• 14.10.BP Pharmaceuticals Laboratories Company

15.Strategic Recommendations

16. About Us Disclaimer